A2 Milk hails research showing its protein variant has different digestive characteristics

Mon, 11 Aug 2014

By Jonathan Underhill Aug. 11 (BusinessDesk) - A2 Milk, which is facing copycat health claims about the A2 beta-casein protein variant in its largest market of Australia, has released a study suggesting the protein doesn't provoke digestive discomfort the way the more common A1 variant does. The Curtin University study, funded by NZX-listed A2 Milk and published in the European Journal of Clinical Nutrition, is the first clinical trial of A1 and A2 milk proteins on human digestion. A2 Milk markets its products as potentially being benefic...
Opinion
PATTRICK SMELLIE: What do the Nats do now?
Pattrick Smellie | Tue, 14 Jul 2020

Todd Muller's only job as National Party leader was to lose the election better than it seemed Simon Bridges was destined to do. Whoever replaces Muller has an even simpler task: save as much of th...

Listed Companies
Huljich family sells 25% of Pushpay stake
Dan Brunskill | Tue, 14 Jul 2020

The Huljich family has sold a quarter of its cornerstone stake in Pushpay Holdings, one of the rising software company stars. The 14.4 million shares were sold for $123.8 million, or $8.60 per shar...

Property
Housing market rebounds sharply; caution required
Jenny Ruth | Tue, 14 Jul 2020

The housing market bounded out of lockdown last month with sales volumes the highest for June in four years and prices nationally up 8.6 percent from a year earlier. The Real Estate Institute's lat...

The role of private equity in the wake of COVID-19

As local covid-19 restrictions ease, a new business cycle is beginning in New Zealand.